Outcomes associated with apixaban vs warfarin in patients with renal dysfunction
- 28 May 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (11), 2366-2371
- https://doi.org/10.1182/bloodadvances.2019000972
Abstract
Apixaban in patients with impaired renal function is supported by limited data. Landmark clinical trials evaluating apixaban in patients with atrial fibrillation and/or acute venous thromboembolism excluded patients with creatinine clearance (CrCl) <25 mL/min. This multicenter, retrospective chart review was conducted to evaluate the safety and effectiveness of apixaban compared with warfarin in patients with CrCl <25 mL/min. Included patients were newly initiated on apixaban or warfarin for at least 45 days with a CrCl <25 mL/min. Patients were evaluated for thrombosis and bleeding outcomes 6 months following initiation of anticoagulation. The primary outcome was the time to first bleeding or thrombosis event. A total of 128 patients met inclusion criteria in the apixaban group and 733 patients in the warfarin group. Time to first bleeding or thrombosis event was significantly different between the apixaban and warfarin groups. Cox proportional hazards model was conducted to control for potential confounding factors for the primary outcome. After controlling for atrial fibrillation and coronary artery bypass grafting, risk of thrombotic and bleeding events was lower in the apixaban group (hazard ratio, 0.47; 95% confidence interval, 0.25-0.92). There was not a statistical difference between time to thrombosis (83 days vs 54 days, P = .648), rate of thrombosis (5.5% vs 10.3%, P = .08), time to bleeding (46 days vs 54 days, P = .886), or rate of bleeding (5.5% vs 10.9%, P = .06). The severity of bleeding and thrombotic events was not different between groups. Apixaban may serve as a reasonable alternative compared with warfarin in patients with severe renal dysfunction.This publication has 25 references indexed in Scilit:
- Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysisThe Journal of Clinical Pharmacology, 2015
- Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixabanThe Journal of Clinical Pharmacology, 2015
- Meta-Analysis on Risk of Bleeding With Apixaban in Patients With Renal ImpairmentThe American Journal of Cardiology, 2015
- 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial FibrillationJournal of the American College of Cardiology, 2014
- CorrectionJournal of the American College of Cardiology, 2014
- Haemostasis in chronic kidney diseaseNephrology Dialysis Transplantation, 2013
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismThe New England Journal of Medicine, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation, 2011
- Dilemmas in the Management of Atrial Fibrillation in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2009